sphingosine-phosphorylcholine and Multiple-Sclerosis

sphingosine-phosphorylcholine has been researched along with Multiple-Sclerosis* in 1 studies

Other Studies

1 other study(ies) available for sphingosine-phosphorylcholine and Multiple-Sclerosis

ArticleYear
Sphingosylphosphorylcholine inhibits plasma cell differentiation and ameliorates experimental autoimmune encephalomyelitis.
    Frontiers in immunology, 2023, Volume: 14

    Multiple sclerosis (MS) is a potentially disabling disease that damages the brain and spinal cord, inducing paralysis of the body. While MS has been known as a T-cell mediated disease, recent attention has been drawn to the involvement of B cells in its pathogenesis. Autoantibodies from B cells are closely related with the damage lesion of central nervous system and worse prognosis. Therefore, regulating the activity of antibody secreting cell could be related with the severity of the MS symptoms.. Collectively, we demonstrate that SPC strongly inhibits plasma cell differentiation, which is mediated by S1PR3. SPC also elicits therapeutic outcomes against EAE, an experimental model of MS, suggesting SPC as a new material to control MS.

    Topics: Animals; Cell Differentiation; Encephalomyelitis, Autoimmune, Experimental; Lipopolysaccharides; Mice; Multiple Sclerosis; Spinal Cord

2023